ReviewNature reviews. Endocrinology2014
The 'omics' of adrenocortical tumours for personalized medicine.
Review in Nature reviews. Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The Utility of Cabozantinib in the Therapy of Endocrine Tumours.Endocrine pathology · 2025Review
- Adrenal Incidentaloma: From Silent Diagnosis to Clinical Challenge.Biomedicines · 2025Review
- Surgery for advanced adrenal malignant disease: recommendations based on European Society of Endocrine Surgeons consensus meeting.The British journal of surgery · 2024Article
- Hereditary Endocrine Tumor Registries.Journal of the Endocrine Society · 2023Article
- Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance.Biomedicines · 2021Review
- Engineering Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis.Journal of endocrinological investigation · 2018Review
- Long Noncoding RNA MEG3 Is an Epigenetic Determinant of Oncogenic Signaling in Functional Pancreatic Neuroendocrine Tumor Cells.Molecular and cellular biology · 2017Article
- Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.Endocrine pathology · 2017Review
- 5th International ACC Symposium: Classification of Adrenocortical Cancers from Pathology to Integrated Genomics: Real Advances or Lost in Translation?Hormones & cancer · 2016Review
- Pediatric adrenocortical tumors: what they can tell us on adrenal development and comparison with adult adrenal tumors.Frontiers in endocrinology · 2015Review
- Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment.Frontiers in cell and developmental biology · 2015Review
- Regulation of the adrenocortical stem cell niche: implications for disease.Nature reviews. Endocrinology · 2015Review
- Article
- Emerging therapy for adrenocortical carcinoma.International journal of endocrine oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pan-genomic analyses of genetic and epigenetic alterations and gene expression profiles are providing important new insights into the pathogenesis and molecular classification of cancers. The technologies and methods used for these studies are rapidly diversifying and improving. The use of such methodologies for the analysis of adrenocortical tumours has revealed clear transcriptomic (mRNA and microRNA expression profiles), epigenomic (DNA methylation profiles) and genomic (DNA mutations and chromosomal alterations) differences between benign and malignant tumours. Interestingly, genomic studies of adrenal cancers have also identified subtypes of malignant tumours, which demonstrate distinct patterns of molecular alterations and are associated with different clinical outcomes. These discoveries have created the opportunity for classifying adrenocortical tumours on the basis of molecular analyses. Following these genomic studies, efforts to develop new molecular tools that improve diagnosis and prognostication of patients with adrenocortical tumours have also been made. This Review describes the progress that has been made towards classification of adrenocortical tumours to date based on key genomic approaches. In addition, the potential for the development and use of various molecular tools to personalize the management of patients with adrenocortical tumours is discussed.
Indexed as
Identifiers
24492180What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.